EMEA-000534-PIP03-17
Key facts
| Active substance |
Mecasermin rinfabate
|
| Therapeutic area |
Neonatology-Paediatric Intensive Care
|
| Decision number |
P/0066/2020
|
| PIP number |
EMEA-000534-PIP03-17
|
| Pharmaceutical form(s) |
Solution for infusion
|
| Condition(s) / indication(s) |
Prevention of chronic lung disease of prematurity
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Oak Hill Bio
Oak Hill Bio |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|